OrbiMed has closed on more than $4 billion in fresh commitments across three funds, riding momentum from a strong year of acquisitions in the pharmaceutical and biotech industries. Tailwinds in drug and therapeutics innovation—combined with pharma and biotech M&A deals that are freeing up LP cash—are driving capital commitments in a dry market. The sector’s rapidly evolving new technology is accelerated by populations aging in key markets, consumers demanding more personalized healthcare and developers applying generative AI to drug discovery.
Read the full article: M&A, Drug Discovery Hype Propel OrbiMed’s $4.3B Healthcare Fund Trio //
Source: https://pitchbook.com/news/articles/ma-drug-discovery-hype-propel-orbimeds-43b-healthcare-fund-trio